Carisma appoints prominent oncologist to SAB; merger on track for Q1 2023

Carisma Therapeutics Inc.

Padmanee Sharma, MD, PhD, from MD Anderson, appointed to Carisma's Scientific Advisory Board.
She brings expertise in immuno-oncology for CAR-M and checkpoint inhibitor combination trials.
Merger with Sesen Bio expected to close in Q1 2023, subject to stockholder approval and conditions.
Phase 1 trial of CT-0508 + Keytruda actively recruiting; first patient anticipated by end of Q1 2023.
Merger agreement amended Dec 29, 2022 to deliver greater value to Sesen Bio stockholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.